Page last updated: 2024-12-09

zuclomiphene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Zuclomiphene: The cis or (Z)-isomer of clomiphene. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1548955
CHEMBL ID167779
CHEBI ID177766
SCHEMBL ID34894
MeSH IDM0004594

Synonyms (93)

Synonym
BB 0262806
AB00053440-08
CHEBI:177766
2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine
BRD-K29950728-048-02-6
triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-
omifin
2-({4-[(z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-n,n-diethylethanamine
IDI1_000462
2-(4-[2-chloro-1,2-diphenylethenyl]phenoxy)-n,n-diethylethanamine
BSPBIO_002053
SPECTRUM5_000757
QTL1_000019
cis-clomiphene
rmi-16312
zuclomiphene
cis-2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
transclomiphene
cisclomifenum
zuclomiphene [usan]
cis-2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethylethanamine
zuclomifene
zuclomifenum [inn-latin]
triethylamine, 2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)-, (z)-
(z)-2-(p-(2-chloro-1,2-diphenylvinyl)phenoxy)triethylamine
zuclomifeno [inn-spanish]
ethanamine, 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethyl-, (z)-
cis-clomifene
NCGC00164385-02
D09037
zuclomiphene (usan)
15690-55-8
CHEMBL167779 ,
rmi-16,312
clomiphene cis-form
isomer a
rmi 16,312
NCGC00164385-03
zuclomifeno
zuclomifene [inn]
zuclomifenum
3ju1du3652 ,
unii-3ju1du3652
dtxcid202843
cas-911-45-5
tox21_113110
AKOS016010299
clomiphene cis-form [mi]
ethanamine, 2-(4-((1z)-2-chloro-1,2-diphenylethenyl)phenoxy)-n,n-diethyl-
BRD-K91328526-048-01-4
2-[4-[(z)-2-chloro-1,2-diphenyl-vinyl]phenoxy]-n,n-diethyl-ethanamine
SCHEMBL34894
NCGC00164385-05
tox21_113110_1
7-trifluoromethoxy-2,3,4,5-tetrahydro-1h-benzo[b]azepinehydrochloride
cis-clomiphene hcl
2,2-difluoroethylaminehydrochloride
clomid (salt/mix)
ardomon (salt/mix)
mrl-41 (salt/mix)
chloramiphene (salt/mix)
2-(p-(.beta.-chloro-.alpha.-phenylstyryl)phenoxy)-triethylamine
1-(p-(.beta.-diethylaminoethoxy)-phenyl)-1,2-diphenylchloroethylene
chloramifene (salt/mix)
GKIRPKYJQBWNGO-QPLCGJKRSA-N
chlomaphene (salt/mix)
bdbm71545
clomiphene, 2
cid_3033832
2-[4-[(z)-2-chloranyl-1,2-diphenyl-ethenyl]phenoxy]-n,n-diethyl-ethanamine;2-oxidanylpropane-1,2,3-tricarboxylic acid
2-[4-[(z)-2-chloro-1,2-diphenyl-vinyl]phenoxy]ethyl-diethyl-amine;citric acid
2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-n,n-diethylethanamine
AB00053440_10
AB00053440_09
(2-{4-[(e)-2-chloro-1,2-diphenylvinyl]phenoxy}ethyl)diethylamine
SBI-0051318.P003
NCGC00164385-06
2-(4-(2-chloro-1,2-diphenylvinyl)-phenoxy)-n,n-diethylethanamine
(z)-2-(4-(2-chloro-1,2-diphenylvinyl)phenoxy)-n,n-diethylethan-1-amine
(e)-clomiphene;trans-clomiphene;enclomifene
cisclomifenum; cis-clomiphene;zuclomifene
BCP27849
clomiphene; clomiphene b
BRD-K29950728-048-08-3
Q27257344
AT36987
cis-clomiphenehcl
DTXSID601317947
bdbm430640
A937583
CS-0019859
HY-A0287
EN300-7479238

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (53)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency21.87610.002541.796015,848.9004AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency26.83253.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency27.12360.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency13.13730.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency4.73590.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency28.43990.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency16.87880.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency29.35480.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.48710.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency27.92380.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.80290.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.17650.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.26930.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency5.95570.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.19770.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency1.38030.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.48890.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency37.90190.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency33.49150.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency3.34910.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency26.11660.001628.015177.1139AID1224895; AID1259385
activating transcription factor 6Homo sapiens (human)Potency26.83250.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency25.373519.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency23.03100.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency56.83180.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.94900.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency29.84700.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.57510.000627.21521,122.0200AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency2.37100.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency20.37680.00339.158239.8107AID1347407; AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency2.37100.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.79430.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Isocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)IC50 (µMol)37.86000.00350.52745.1760AID1513037
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)5.36000.00022.45859.9600AID1804171
C-8 sterol isomeraseSaccharomyces cerevisiae S288CKi0.00200.00000.90487.1500AID239296
Testosterone 17-beta-dehydrogenase 3Homo sapiens (human)IC50 (µMol)76.20000.00261.76469.3000AID1799665
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.18200.00091.901410.0000AID576612
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)Ki0.00200.00040.54906.7000AID239597
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.00500.00000.490110.0000AID239347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (214)

Processvia Protein(s)Taxonomy
glyoxylate cycleIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
tricarboxylic acid cycleIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
isocitrate metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
2-oxoglutarate metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
glutathione metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
response to oxidative stressIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
female gonad developmentIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
response to steroid hormoneIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
regulation of phospholipid catabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
regulation of phospholipid biosynthetic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
NADP metabolic processIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
androgen biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
male genitalia developmentTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
steroid biosynthetic processTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cholesterol biosynthetic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol metabolic process3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
hemopoiesis3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via desmosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholesterol biosynthetic process via lathosterol3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
ossification involved in bone maturation3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (81)

Processvia Protein(s)Taxonomy
magnesium ion bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
isocitrate dehydrogenase (NADP+) activityIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
protein bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
identical protein bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
protein homodimerization activityIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cadherin bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
NADP bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
NAD bindingIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
estradiol 17-beta-dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activityTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C-8 sterol isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
steroid delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
identical protein binding3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cholestenol delta-isomerase activity3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
extracellular regionIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytoplasmIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
peroxisomeIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
peroxisomal matrixIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytosolIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
secretory granule lumenIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
extracellular exosomeIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
tertiary granule lumenIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
ficolin-1-rich granule lumenIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
cytosolIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
mitochondrionIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
peroxisomeIsocitrate dehydrogenase [NADP] cytoplasmicHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulum membraneTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
intracellular membrane-bounded organelleTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
endoplasmic reticulumTestosterone 17-beta-dehydrogenase 3Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
nuclear envelope3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
cytoplasmic vesicle3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
nuclear membrane3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
endoplasmic reticulum3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID55146Inhibitory concentration against ethidium bromide binding to DNA1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer.
AID1513037Inhibition of IDH1 R132H mutant in human HT-1080 cells assessed as suppression of 2-HG production incubated for 48 hrs by LC-MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID239347Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID213588The compound was tested for relative binding affinity against calf uterine receptor using [3H]estradiol as radioligand1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Ellipticine derivatives with an affinity to the estrogen receptor, an approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer.
AID239597Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID239296Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1799665Inhibition Assay from Article 10.1080/14756360109162353: \\Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.\\2001Journal of enzyme inhibition, Jan, Volume: 16, Issue:1
Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.88)18.7374
1990's0 (0.00)18.2507
2000's2 (11.76)29.6817
2010's7 (41.18)24.3611
2020's7 (41.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.80 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index47.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome [NCT01157312]113 participants (Actual)Interventional2008-08-31Completed
Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene [NCT01289756]Phase 120 participants (Actual)Interventional2009-12-31Completed
Effect of Sildenafil Citrate Compared to Estrogen as Adjuvant Therapy on Improvement of Endometrial Thickness and Treatment of Unexplained Infertility [NCT05753098]Phase 4148 participants (Actual)Interventional2021-01-15Completed
Evaluate the Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination [NCT01219101]Phase 495 participants (Actual)Interventional2011-03-31Completed
Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial [NCT02523898]Phase 2388 participants (Anticipated)Interventional2015-11-30Enrolling by invitation
"Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility:A Clinical Research of Same Treatment for Different Diseases" [NCT03709849]Phase 2528 participants (Anticipated)Interventional2019-02-01Not yet recruiting
Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome [NCT02344888]Phase 4300 participants (Anticipated)Interventional2015-02-28Recruiting
A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects [NCT02117830]Phase 154 participants (Anticipated)Interventional2014-04-30Completed
FSH and LH Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women [NCT01340521]Phase 1/Phase 225 participants (Actual)Interventional1991-03-31Completed
PHASE 2b RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY OF ANDROXAL IN IDIOPATHIC MALE INFERTILITY (PROTOCOL #01-14-40-08) [NCT02160704]Phase 2/Phase 30 participants (Actual)Interventional2014-09-22Withdrawn(stopped due to Difficult eligibility and lack of funding)
Intrauterine Infusion of Autologous Platelet-rich Plasma to Prevent a Thin Endometrium in Infertile Women Undergoing Clomiphene Citrate Therapy: a Pilot Prospective Self-controlled Trial [NCT03770026]Phase 2/Phase 330 participants (Actual)Interventional2018-01-01Completed
Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial [NCT02479256]Phase 4600 participants (Actual)Interventional2015-06-30Completed
Trigger or Not to Trigger? : An Answer for an Old Question [NCT02264847]Phase 3200 participants (Anticipated)Interventional2014-10-31Recruiting
Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole [NCT03241472]Phase 3100 participants (Actual)Interventional2016-02-29Completed
Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility [NCT03681197]Early Phase 1170 participants (Anticipated)Interventional2018-06-15Recruiting
Evaluation of the Clinical Outcome of Vitamin E as Adjuvant Therapy in Patients With Clomiphene Citrate Resistant Polycystic Ovary Syndrome [NCT03674385]Phase 260 participants (Actual)Interventional2018-07-19Completed
Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome [NCT03630341]Phase 4150 participants (Actual)Interventional2016-02-01Completed
Effects of Vitamin D Supplementation on Reproductive, Hormonal and Metabolic Profiles, and on IVF Outcomes, in PCOS Infertile Saudi Women : a Randomized-controlled Clinical Trial [NCT05106712]700 participants (Anticipated)Interventional2021-11-01Not yet recruiting
Effect of Adding Vitamin D Supplement to Clomiphene Citrate for Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome [NCT03396380]Phase 3186 participants (Anticipated)Interventional2017-07-01Recruiting
Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility: Randomized Controlled Trial [NCT03549741]Phase 2/Phase 3120 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome [NCT02255578]Phase 350 participants (Anticipated)Interventional2014-09-30Not yet recruiting
Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial [NCT02186782]Phase 4600 participants (Anticipated)Interventional2014-06-30Recruiting
Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF: a Randomized Study [NCT02201914]Phase 4250 participants (Anticipated)Interventional2014-01-31Recruiting
The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial [NCT01213147]Phase 4159 participants (Actual)Interventional2009-04-30Completed
Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer [NCT03646162]Phase 293 participants (Actual)Interventional2018-09-14Completed
L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome [NCT03476356]106 participants (Actual)Interventional2017-11-01Completed
Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Non Polycystic Ovarian Syndrome Patients [NCT02330757]Phase 4150 participants (Anticipated)Interventional2016-10-10Recruiting
Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination [NCT01232075]Phase 2214 participants (Actual)Interventional2008-09-30Completed
Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer [NCT03309436]Phase 4360 participants (Anticipated)Interventional2017-08-07Recruiting
Combined Coenzyme Q10 and Clomiphene Citrate for Ovulation Induction in Clomiphene-citrate-resistant Polycystic Ovary Syndrome [NCT04302532]Phase 4149 participants (Actual)Interventional2020-07-01Completed
Effect of Sildenafil Citrate on Pregnancy Rate in Women Undergoing Induction of Ovulation [NCT02890238]Phase 4100 participants (Anticipated)Interventional2016-08-31Recruiting
Comparison of Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF: a Prospective Cohort Study [NCT02690870]Phase 4210 participants (Anticipated)Interventional2017-01-31Not yet recruiting
A Comparison of Clomiphene Citrate Responses in Men With Hypothalamic Hypogonadism naïve to, and Previously Treated With, Testosterone [NCT01904734]Phase 242 participants (Actual)Interventional2012-10-31Completed
Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects. [NCT02380755]Phase 278 participants (Actual)Interventional2015-04-30Completed
Prospective Randomized Trial on the Effect of Clomiphene Citrate Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and Pregnancy Outcome. [NCT02237755]Phase 2/Phase 350 participants (Anticipated)Interventional2014-10-31Not yet recruiting
Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome [NCT02802865]Phase 470 participants (Actual)Interventional2016-08-31Completed
Combined Pioglitazone and Clomophene Citrate Versus Combined Metformin and Clomiphene Citrate as First Treatment in Infertile Women With Polycystic Ovary Syndrome [NCT03566225]Early Phase 1400 participants (Actual)Interventional2018-01-30Completed
Effect of Ubiquinol Supplementation on Ovulation Induction in Clomiphene Citrate Resistance [NCT04870502]Phase 2/Phase 3161 participants (Actual)Interventional2019-04-01Completed
Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome [NCT02436226]Phase 4300 participants (Actual)Interventional2016-03-31Completed
Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome [NCT02551367]Phase 2110 participants (Anticipated)Interventional2015-10-31Not yet recruiting
Pharmacokinetics and Hepatic Safety of EGCG [NCT04177693]Phase 139 participants (Actual)Interventional2020-11-24Completed
Myo-inositol Versus Clomiphene Citrate as First Line Treatment for Ovulation Induction in PCOS [NCT04306692]Phase 412 participants (Actual)Interventional2020-07-02Terminated(stopped due to clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome)
N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial [NCT02775734]Phase 2/Phase 3144 participants (Actual)Interventional2016-05-31Completed
Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility [NCT02644304]Phase 288 participants (Anticipated)Interventional2015-05-31Recruiting
A Comparison of Hormonal Profile and the Follicular Development Between Letrozole and Clomifene Citrate in Anovulatory Women With Polycystic Ovary Syndrome and Ovulatory Women [NCT02647424]40 participants (Anticipated)Interventional2015-12-31Recruiting
Oral Sildenafil Citrate: a Potential Approach for Improvement of Endometrial Thickness and Treatment of Unexplained Infertility in Women [NCT05846906]Phase 2/Phase 3130 participants (Actual)Interventional2021-10-01Completed
Among Non-IVF Patients Undergoing Ovulation Induction With Clomiphene Citrate (Clomid® 50 mg), Does Administration of an Increased Dose of Clomiphene Citrate (Clomid® 100 mg) Compared With Gonadotropins, Achieve Similar Rates of Folliculogenesis? [NCT00835744]Phase 440 participants (Actual)Interventional2008-08-31Completed
Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism [NCT00697814]Phase 215 participants (Actual)Interventional2004-06-30Completed
Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome [NCT00795808]Phase 4171 participants (Actual)Interventional2003-08-31Completed
The Effect of Incremental Clomiphene Citrate(CC) Doses in Successive Induction Cycles on the Endogenous Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Steroid Hormone Responses to Treatment [NCT04210765]Phase 450 participants (Actual)Interventional2019-08-02Completed
Protocol to Minimize Injections and Blood Draws for Women Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization [NCT02865681]4 participants (Actual)Interventional2016-07-01Completed
An Open, Randomized, Parallel-Group, Multicentric, Comparative Study of Letrozole With Clomiphene Citrate for Induction of Ovulation in Anovulatory Infertility. [NCT00610077]Phase 355 participants (Actual)Interventional2004-12-31Completed
A One Year Open Label Study of Androxal in the Treatment of Secondary Hypogonadism in Men Who Have Completed Protocol ZA-203 [NCT01386567]Phase 248 participants (Actual)Interventional2011-07-31Completed
Evaluation of the Effect of Pentoxifylline and α-Lipoic Acid as Adjunctive Therapy in Patients With Clomiphene Citrate Resistant Polycystic Ovary Syndrome [NCT05231980]Phase 2120 participants (Actual)Interventional2022-06-05Completed
Mild Stimulation Protocol Using Clomiphene Citrate / Gonadotropins Versus Conventional Stimulation Protocol for Women With PCOS Undergoing in Vitro Fertilization (IVF): a Prospective Non-randomized Controlled Trial [NCT04157725]Phase 4154 participants (Anticipated)Interventional2023-06-01Active, not recruiting
Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients [NCT02544776]60 participants (Actual)Interventional2015-01-31Completed
Different Variables Predicting Ovulatory Response Among Clomiphene Citrate Resistance and Clomiphene Citrate Sensitive Patients With Polycystic Ovarian Syndrome. [NCT04887402]100 participants (Anticipated)Observational [Patient Registry]2021-01-01Recruiting
Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study [NCT01004068]Phase 496 participants (Actual)Interventional2008-02-29Completed
An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxalâ„¢ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003 [NCT01067365]Phase 3104 participants (Actual)Interventional2006-03-31Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxalâ„¢ Treatment in Men With Secondary Hypogonadism [NCT00962637]Phase 3194 participants (Actual)Interventional2006-03-31Completed
[NCT00844350]Phase 2177 participants (Actual)Interventional2006-10-31Completed
Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome [NCT00427700]Phase 382 participants (Actual)Interventional2008-08-31Completed
Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome [NCT01910766]110 participants (Actual)Interventional2010-01-31Completed
Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate [NCT05096169]Phase 240 participants (Anticipated)Interventional2022-05-01Recruiting
AN OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE DRUG-DRUG INTERACTIONS OF ANDROXAL WITH CYTOCHROME P450 ISOENZYMES IN HEALTHY MALE SUBJECTS [NCT01991327]Phase 130 participants (Actual)Interventional2014-05-31Completed
Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial [NCT02024984]Phase 190 participants (Anticipated)Interventional2013-11-30Recruiting
Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest [NCT02575248]Phase 4310 participants (Anticipated)Interventional2014-10-31Recruiting
Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome. [NCT00830492]Phase 4200 participants (Anticipated)Interventional2008-01-31Completed
The Added Value of n Acetyle Cysteine and Chromium to Clomiphene Citrate in PCO [NCT04170439]108 participants (Actual)Interventional2019-11-20Completed
The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial. [NCT02663830]Phase 2210 participants (Actual)Interventional2016-01-10Completed
Patients With Reduced Ovarian Reserve and In Vitro Fertilization (IVF) Cycles. A Randomized Multicentric Comparison of a Protocol With High Doses of Gonadotropins and a Protocol With Clomiphene Citrate Only. Evaluation of Clinical Effectiveness and Econom [NCT01389713]289 participants (Actual)Interventional2008-09-30Completed
Cost-effective Treatment of Unexplained Infertility: A Prospective Multicenter, Double-blinded, Randomised Controlled Study [NCT06178523]Phase 4900 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome [NCT00471523]Phase 480 participants (Actual)Interventional2006-05-31Completed
Comparison of Recombinant Follicle Stimulating Hormone and the Combination of Recombinant Follicle Stimulating Hormone With Clomiphene Citrate in Stimulated Intrauterine Insemination Cycles: A Prospective Randomized Controlled Multicentric Study [NCT05670795]254 participants (Anticipated)Interventional2023-01-01Recruiting
Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial: The Role of Progestin-induced Endometrial Shedding in PCOS (PIES in PCOS) [NCT01718444]27 participants (Actual)Interventional2015-03-31Terminated(stopped due to The primary investigator moved from academic practice to join a private group, and could not get any one to take over as PI for the study.)
Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate [NCT00449514]100 participants (Anticipated)Interventional2007-05-31Recruiting
How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study. [NCT00501839]Phase 40 participants (Actual)Interventional2008-08-31Withdrawn
What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study. [NCT00502229]Phase 40 participants (Actual)Interventional2010-01-31Withdrawn
Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial [NCT00558077]Phase 450 participants (Actual)Interventional2003-02-28Completed
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome: Randomised Control Trial [NCT05702957]Phase 2/Phase 3220 participants (Actual)Interventional2016-09-30Completed
A Randomized Double Blinded Placebo Controlled Trial Between Anastrozole and Clomiphene to Evaluate Improvement in Hypogonadal Symptoms and Erectile Function Using ADAM, IIEF and EHS Validated Scales [NCT03933618]Phase 224 participants (Actual)Interventional2015-04-02Completed
Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome [NCT00068861]Phase 3678 participants Interventional2002-11-30Completed
Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Polycystic Ovarian Syndrome Patients [NCT02273791]126 participants (Actual)Observational2013-12-31Completed
Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome [NCT00478504]Phase 4159 participants (Actual)Interventional2007-05-31Completed
Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial [NCT00461643]Phase 4552 participants (Anticipated)Interventional2007-01-31Recruiting
Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia [NCT01529177]Phase 4600 participants (Anticipated)Interventional2012-02-29Recruiting
The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial [NCT00413179]Phase 356 participants Interventional1997-12-31Completed
Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial. [NCT01791751]Phase 410 participants (Actual)Interventional2012-06-30Completed
A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism [NCT01270841]Phase 283 participants (Actual)Interventional2011-01-31Completed
A Double-Blind Crossover Study In Healthy Volunteers to Compare Two Formulations of Androxal [NCT01984398]Phase 116 participants (Actual)Interventional2013-12-31Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Administered Intravenously or Subcutaneously (Via Portable Infusion Pump) Compared to Oral Treatment With Clomi [NCT00296465]Phase 2/Phase 3132 participants (Actual)Interventional2005-02-28Completed
A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism [NCT01619683]Phase 3300 participants (Actual)Interventional2012-09-30Completed
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome (PCOS) and a Resistance to Insulin. Randomised Controlled Study [NCT01638988]Phase 30 participants (Actual)Interventional2013-09-30Withdrawn(stopped due to Previous studies have been done regarding same condition)
An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism [NCT01739582]Phase 3300 participants (Anticipated)Interventional2012-11-30Completed
[NCT01784380]1,159 participants (Actual)Observational2006-10-31Completed
Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women [NCT01793038]160 participants (Anticipated)Interventional2013-03-31Recruiting
A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment [NCT01191320]Phase 2102 participants (Actual)Interventional2010-10-31Completed
A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men [NCT01386606]Phase 260 participants (Actual)Interventional2011-06-30Completed
Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial [NCT01008319]Phase 3120 participants (Actual)Interventional2009-10-31Completed
Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome [NCT02352597]Phase 4150 participants (Actual)Interventional2013-01-31Completed
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment With Clomiphene Citr [NCT00796289]Phase 2350 participants (Actual)Interventional2009-02-28Completed
[NCT00005104]99 participants Interventional2000-01-31Completed
A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function [NCT01923857]Phase 126 participants (Actual)Interventional2013-08-31Completed
Clomiphene Citrate Stair-step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome: A Randomized Clinical Trial [NCT03178500]60 participants (Anticipated)Interventional2017-02-01Recruiting
Randomized Prospective Controlled Non-inferiority Trial of Low-dose Clomiphene Based Antagonist Protocol vs. High Dose Gonadotropin/Antagonist Protocol for IVF Poor Responders [NCT01577199]Phase 40 participants (Actual)Interventional2012-04-30Withdrawn(stopped due to no subjects recruited)
An Open Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Hepatic Function [NCT01923870]Phase 119 participants (Actual)Interventional2013-08-31Completed
Effect of High BMI on Ovulation Induction Using Letrozole Versus Clomid [NCT04331197]Phase 4160 participants (Anticipated)Interventional2020-05-01Not yet recruiting
[NCT00005654]88 participants Interventional2000-01-31Completed
Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome [NCT01909141]Early Phase 1100 participants (Actual)Interventional2013-08-31Completed
A Dose Escalating Study To Determine the Tolerability and Pharmacokinetics of a Single Dose of Androxal in Healthy Volunteers [NCT01959685]Phase 19 participants (Actual)Interventional2013-10-31Completed
Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial [NCT02710981]42 participants (Actual)Interventional2015-06-30Completed
Interest of Clomiphene Citrate (CC) Associated With a Second Testicular Sperm Extraction (TESE) in Patients With Non-obstructive Azoospermia (NOA) After Failure of a First TESE, on the Quantity of Sperm Cells Available for Intracytoplasmic Sperm Injection [NCT03615547]Phase 3128 participants (Anticipated)Interventional2023-01-31Not yet recruiting
Extended Clomiphene Citrate Regimen Versus Laparoscopic Ovarian Drilling for Ovulation Induction in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome [NCT02381184]Phase 2/Phase 3160 participants (Actual)Interventional2014-06-30Completed
Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome [NCT03316469]40 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles [NCT02345837]160 participants (Anticipated)Interventional2014-02-28Recruiting
An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism [NCT01534208]Phase 3499 participants (Actual)Interventional2012-05-31Completed
A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration [NCT01532414]Phase 3151 participants (Actual)Interventional2012-08-31Completed
A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone. [NCT00706719]Phase 217 participants (Actual)Interventional2008-06-30Completed
Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial [NCT05089344]132 participants (Anticipated)Interventional2021-10-09Recruiting
Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting [NCT03028532]Phase 112 participants (Actual)Interventional2017-03-13Completed
A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration [NCT01739595]Phase 3181 participants (Actual)Interventional2012-11-30Completed
A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile [NCT00213148]Phase 2271 participants (Actual)Interventional2005-03-10Completed
Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial [NCT04944836]Phase 258 participants (Anticipated)Interventional2023-03-09Recruiting
Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation [NCT01044862]Phase 3900 participants (Actual)Interventional2010-06-30Completed
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation [NCT05206448]Phase 4189 participants (Actual)Interventional2020-10-26Active, not recruiting
A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome [NCT00719186]Phase 3750 participants (Actual)Interventional2009-02-28Completed
The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovarian Syndrome [NCT03806036]Phase 4100 participants (Anticipated)Interventional2018-01-02Recruiting
Comparative Study of Pregnancy Rate After Endometrial Injury in Couples With Unexplained Infertility [NCT03398993]100 participants (Anticipated)Interventional2018-01-31Not yet recruiting
Determining the Fertility Benefit of Immediate SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis [NCT02520505]0 participants (Actual)Interventional2015-04-30Withdrawn(stopped due to no participants enrolled)
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome During Induction of Ovulation With Clomiphene Citrate [NCT03059173]Phase 3276 participants (Anticipated)Interventional2022-03-31Not yet recruiting
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 m [NCT02651688]Phase 250 participants (Actual)Interventional2016-01-11Completed
Clomiphene Citrate for the Treatment of Opioid-Induced Androgen Deficiency: Randomized Controlled Clinical Trial [NCT01880086]Phase 213 participants (Actual)Interventional2013-08-31Completed
Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies [NCT02274311]Phase 216 participants (Actual)Interventional2011-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00213148 (2) [back to overview]Number of Subjects With Clinical Pregnancy in Cycle 1
NCT00213148 (2) [back to overview]Ovulation Rate in Cycle 1
NCT00427700 (2) [back to overview]Percentage of Participants With Ovulation Detected by Ultrasound
NCT00427700 (2) [back to overview]Serum Levels of Progesterone
NCT00706719 (5) [back to overview]Sperm Concentration
NCT00706719 (5) [back to overview]Follicle Stimulating Hormone (FSH) Levels
NCT00706719 (5) [back to overview]Semen Volume
NCT00706719 (5) [back to overview]Motile Total Sperm Count
NCT00706719 (5) [back to overview]Luteinizing Hormone (LH) Levels
NCT00719186 (5) [back to overview]Number of Serious Adverse Events
NCT00719186 (5) [back to overview]Number of Pregnancy
NCT00719186 (5) [back to overview]Number of Ovulations
NCT00719186 (5) [back to overview]Live Birth
NCT00719186 (5) [back to overview]Neonatal Complication Rate
NCT01008319 (2) [back to overview]Time to Ovulation With Each Protocol
NCT01008319 (2) [back to overview]Delivery Outcomes
NCT01044862 (4) [back to overview]Time to Pregnancy
NCT01044862 (4) [back to overview]Rate of Pregnancy Obtained
NCT01044862 (4) [back to overview]Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.
NCT01044862 (4) [back to overview]Live Birth Rate
NCT01191320 (1) [back to overview]Change in HbA1C
NCT01270841 (4) [back to overview]Change in FSH After 3 Months of Treatment
NCT01270841 (4) [back to overview]Change in Luteinizing Hormone Levels
NCT01270841 (4) [back to overview]Change in Total Morning Testosterone
NCT01270841 (4) [back to overview]Reproductive Safety
NCT01386606 (7) [back to overview]24 Hour Average and Maximum Testosterone Concentration
NCT01386606 (7) [back to overview]Morning Testosterone Correlated With Serial Testosterone.
NCT01386606 (7) [back to overview]Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.
NCT01386606 (7) [back to overview]Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.
NCT01386606 (7) [back to overview]Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.
NCT01386606 (7) [back to overview]Change in Follicle Stimulating Hormone (FSH)
NCT01386606 (7) [back to overview]Change in Leuteinizing Hormone (LH)
NCT01532414 (2) [back to overview]Subjects With 50% or Greater Decrease in Sperm Concentration Comparison of Proportion of Subjects With 50% or Greater Decrease in Sperm
NCT01532414 (2) [back to overview]Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range
NCT01534208 (6) [back to overview]Change From Baseline in Total Morning Testosterone at 26 Weeks
NCT01534208 (6) [back to overview]Mean Change From Baseline FPG
NCT01534208 (6) [back to overview]Absolute Values of Morning Testosterone
NCT01534208 (6) [back to overview]Change From Baseline in BMI
NCT01534208 (6) [back to overview]Change From Baseline in FSH
NCT01534208 (6) [back to overview]Change From Baseline in LH
NCT01739595 (2) [back to overview]Subjects With Testosterone in Normal Range After Treatment
NCT01739595 (2) [back to overview]Change in Sperm Concentration
NCT01880086 (7) [back to overview]Androgen Deficiency in the Aging Male (ADAM) Questionnaire
NCT01880086 (7) [back to overview]Estradiol
NCT01880086 (7) [back to overview]Hematocrit (%)
NCT01880086 (7) [back to overview]Men's Sexual Health Questionnaire (MSHQ) Questionnaire
NCT01880086 (7) [back to overview]Other Hormonal Profile (Change From Baseline)
NCT01880086 (7) [back to overview]Serum Total Testosterone (Change From Baseline)
NCT01880086 (7) [back to overview]Sexual Health Inventory for Men (SHIM) Questionnaire
NCT01909141 (5) [back to overview]Number of Follicles>18mm.
NCT01909141 (5) [back to overview]Pregnancy Rate
NCT01909141 (5) [back to overview]Safety of Pioglitazone as Regards Serum Creatinine
NCT01909141 (5) [back to overview]Ovulation Rate
NCT01909141 (5) [back to overview]Endometrial Thickness
NCT01959685 (2) [back to overview]Cmax of a Single Dose of 250 mg Androxal
NCT01959685 (2) [back to overview]Pharmacokinetics
NCT01984398 (2) [back to overview]Androxal Cmax Formulation A
NCT01984398 (2) [back to overview]Androxal Cmax Formulation B
NCT02274311 (3) [back to overview]Testosterone Levels
NCT02274311 (3) [back to overview]IGF-1 Levels
NCT02274311 (3) [back to overview]PSA Levels
NCT02651688 (20) [back to overview]Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Body Mass Index (BMI) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Body Strength (Chest Press Weight) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Body Strength (Leg Press Weight) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Lean Body Mass (LBM) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Waist Circumference at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Weight at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Estradiol (E2) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Leptin Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Testosterone (T) Level at Week 48
NCT02651688 (20) [back to overview]Change From Baseline in Blood Glucose Level at Week 48
NCT02710981 (3) [back to overview]Uterine Blood Flow
NCT02710981 (3) [back to overview]Endometrial Thickness
NCT02710981 (3) [back to overview]Clinical Pregnancy Rate
NCT02802865 (9) [back to overview]Endometrial Thickness
NCT02802865 (9) [back to overview]Conception
NCT02802865 (9) [back to overview]Clinical Pregnancy
NCT02802865 (9) [back to overview]Live Birth
NCT02802865 (9) [back to overview]Size of Largest Developing Follicle
NCT02802865 (9) [back to overview]Pregnancy Loss
NCT02802865 (9) [back to overview]Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level
NCT02802865 (9) [back to overview]Number of Developing Follicles
NCT02802865 (9) [back to overview]Multiple Gestation
NCT03646162 (9) [back to overview]Post-hoc Analysis on the Percentage Change in Frequency of Moderate and Severe Hot Flashes From Baseline to Week 12; Exposure Response Assessment
NCT03646162 (9) [back to overview]Percentage Change in Severity of Moderate to Severe Hot Flashes at 6 Weeks
NCT03646162 (9) [back to overview]Change of Frequency of Moderate to Severe Hot Flashes at Week 12
NCT03646162 (9) [back to overview]Change in Severity of Moderate to Severe Hot Flashes at Week 12
NCT03646162 (9) [back to overview]Change in Serum SHBG
NCT03646162 (9) [back to overview]Change in Serum Free Testosterone
NCT03646162 (9) [back to overview]Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks
NCT03646162 (9) [back to overview]Change in Bone Turnover Markers C-telopeptide (CTX)
NCT03646162 (9) [back to overview]Change in Bone Turnover Markers Alkaline Phosphatase
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 24
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 24
NCT03933618 (95) [back to overview]Estradiol - Week 24
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 16
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 16
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 16
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 24
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SEP #1-3 Cumulative - Week 8
NCT03933618 (95) [back to overview]SHBG - Screen
NCT03933618 (95) [back to overview]SHBG - Screen
NCT03933618 (95) [back to overview]SHBG - Week 16
NCT03933618 (95) [back to overview]SHBG - Week 16
NCT03933618 (95) [back to overview]SHBG - Week 24
NCT03933618 (95) [back to overview]SHBG - Week 24
NCT03933618 (95) [back to overview]SHBG - Week 24
NCT03933618 (95) [back to overview]SHBG - Week 8
NCT03933618 (95) [back to overview]SHBG - Week 8
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 8
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Screen
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 16
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 16
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 24
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 24
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 24
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 8
NCT03933618 (95) [back to overview]ADAM (Androgen Deficiency in the Aging Male) Score - Week 8
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Screen
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 16
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 16
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 24
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 24
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 24
NCT03933618 (95) [back to overview]EHS (Erectile Hardness Score) - Week 8
NCT03933618 (95) [back to overview]Estradiol - Screen
NCT03933618 (95) [back to overview]Estradiol - Screen
NCT03933618 (95) [back to overview]Estradiol - Week 16
NCT03933618 (95) [back to overview]Estradiol - Week 16
NCT03933618 (95) [back to overview]Estradiol - Week 16
NCT03933618 (95) [back to overview]Estradiol - Week 24
NCT03933618 (95) [back to overview]Estradiol - Week 24
NCT03933618 (95) [back to overview]Estradiol - Week 8
NCT03933618 (95) [back to overview]Estradiol - Week 8
NCT03933618 (95) [back to overview]Estradiol - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Screen
NCT03933618 (95) [back to overview]Free Testosterone - Screen
NCT03933618 (95) [back to overview]Free Testosterone - Screen
NCT03933618 (95) [back to overview]Free Testosterone - Week 16
NCT03933618 (95) [back to overview]Free Testosterone - Week 16
NCT03933618 (95) [back to overview]Free Testosterone - Week 16
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 24
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]Free Testosterone - Week 8
NCT03933618 (95) [back to overview]FSH - Screen
NCT03933618 (95) [back to overview]FSH - Screen
NCT03933618 (95) [back to overview]FSH - Week 16
NCT03933618 (95) [back to overview]FSH - Week 24
NCT03933618 (95) [back to overview]FSH - Week 16
NCT03933618 (95) [back to overview]FSH - Week 24
NCT03933618 (95) [back to overview]FSH - Week 24
NCT03933618 (95) [back to overview]FSH - Week 8
NCT03933618 (95) [back to overview]FSH - Week 8
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Screen
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 16
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 16
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 24
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 24
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 24
NCT03933618 (95) [back to overview]IIEF (International Index of Erectile Function) Score - Week 8
NCT03933618 (95) [back to overview]LH - Screen
NCT03933618 (95) [back to overview]LH - Screen
NCT03933618 (95) [back to overview]LH - Week 16
NCT03933618 (95) [back to overview]LH - Week 16
NCT03933618 (95) [back to overview]LH - Week 24
NCT03933618 (95) [back to overview]LH - Week 24
NCT03933618 (95) [back to overview]LH - Week 24
NCT03933618 (95) [back to overview]LH - Week 8
NCT03933618 (95) [back to overview]LH - Week 8
NCT03933618 (95) [back to overview]Normalized Testosterone - Screen
NCT03933618 (95) [back to overview]Normalized Testosterone - Screen
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 16
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 16
NCT03933618 (95) [back to overview]Normalized Testosterone - Week 24
NCT04177693 (11) [back to overview]Changes in Epicatechin Gallate(ECG)
NCT04177693 (11) [back to overview]Changes in Endometrial Thickness
NCT04177693 (11) [back to overview]Changes in ALT/SGPT
NCT04177693 (11) [back to overview]Changes in Alkaline Phosphatase
NCT04177693 (11) [back to overview]Change in Serum Folate Level Between MTHFR677-Wild Type (WT) Group and MTHFR677-Hetero Group
NCT04177693 (11) [back to overview]Change in Serum Folate Level Between MTHFR1298-Wild Type (WT) Group and MTHFR1298-Hetero Group
NCT04177693 (11) [back to overview]Change in Serum Folate Level Between DHFR-Wild Type (WT) Group and DHFR-Hetero or Homo Group.
NCT04177693 (11) [back to overview]Changes in Total Bilirubin
NCT04177693 (11) [back to overview]Changes in Estrogen (E2)
NCT04177693 (11) [back to overview]Changes in Epigallocatechin (EGC)
NCT04177693 (11) [back to overview]Changes in Epigallocatechin Gallate (EGCG)

Number of Subjects With Clinical Pregnancy in Cycle 1

Clinical pregnancy was defined as the existence of at least one ultrasonographically confirmed gestational sac in the uterus with fetal heart activity. (NCT00213148)
Timeframe: Up to 1 month

Interventionsubjects (Number)
Clomiphene Citrate 50 mg10
Anastrozole 1 mg4
Anastrozole 5 mg7
Anastrozole 10 mg0

[back to top]

Ovulation Rate in Cycle 1

Ovulation rate was defined as the percentage of subjects who ovulated (mid-luteal Progesteron [P4] level greater than or equal to [>=] 10 nanogram per milliliter [ng/mL] and/or pregnancy). (NCT00213148)
Timeframe: Up to 1 month

Interventionpercentage of subjects (Number)
Clomiphene Citrate 50 mg64.9
Anastrozole 1 mg30.4
Anastrozole 5 mg36.8
Anastrozole 10 mg35.9

[back to top]

Percentage of Participants With Ovulation Detected by Ultrasound

Ovulation detected by ultrasound was defined as the percentage of a participants with ovulation detected by ultrasound, defined as the dominant follicle and its subsequent collapse. If a dominant follicle was not observed by day 21 after menses, the ovulation induction was considered to be a failure. (NCT00427700)
Timeframe: cycle day 14-20

Interventionpercentage of participants (Number)
Clomiphene52.5
Raloxifene40.4

[back to top]

Serum Levels of Progesterone

The level of serum progesterone that indicated ovulation was considered to be 3 ng/mL or greater, on days 8 to 10 after ovulation. (NCT00427700)
Timeframe: 8-10 days after ovulation

Interventionng/mL (Mean)
Clomiphene26.1
Raloxiphene40

[back to top]

Sperm Concentration

Total sperm concentration was measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
Interventionmillions sperm/mL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim0.543.0023.1421.03
Group B Androxal no Wash Out72.8182.6168.5164.0

[back to top]

Follicle Stimulating Hormone (FSH) Levels

FSH levels were measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
InterventionmIU/mL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim3.381.060.93.6
Group B Androxal no Wash Out1.584.535.482.38

[back to top]

Semen Volume

Semen volume was measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
InterventionmL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim2.342.881.903.34
Group B Androxal no Wash Out2.232.452.482.40

[back to top]

Motile Total Sperm Count

Motile total sperm count was measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
Interventionmillions sperm (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim0.32.4240.438
Group B Androxal no Wash Out99.0214.7146.9100.3

[back to top]

Luteinizing Hormone (LH) Levels

LH levels were measured. (NCT00706719)
Timeframe: Baseline, Month 3, Month 6, Follow-Up (Month 7)

,
InterventionmIU/mL (Mean)
BaselineMonth 3Month 6Follow-Up (Month 7)
Group A Testim3.400.880.602.68
Group B Androxal no Wash Out2.925.706.122.47

[back to top]

Number of Serious Adverse Events

(NCT00719186)
Timeframe: as few as 5 months, up to 16 months

Interventionevents (Number)
Arm A: Clomiphene Citrate13
Arm B: Letrozole22

[back to top]

Number of Pregnancy

(NCT00719186)
Timeframe: as few as 5 months, up to 16 months

InterventionParticipants (Count of Participants)
Arm A: Clomiphene Citrate103
Arm B: Letrozole154

[back to top]

Number of Ovulations

(NCT00719186)
Timeframe: as few as 5 months, up to 16 months

Interventionovulations (Number)
Arm A: Clomiphene Citrate331
Arm B: Letrozole388

[back to top]

Live Birth

The primary outcome measure is the occurrence of a live birth during the study period. Safety measures will be the number and type of reported adverse events in subjects and offspring. (NCT00719186)
Timeframe: as few as 5 months, up to 16 months

InterventionParticipants (Count of Participants)
Arm A: Clomiphene Citrate72
Arm B: Letrozole103

[back to top]

Neonatal Complication Rate

(NCT00719186)
Timeframe: September 2008 - December 2011

,
Interventionparticipants (Number)
Neonatal jaundiceNeonatal respiratory distress syndromeNeonatal hospitalization >3 daysIntrauterine growth restrictionNeonatal infectinMinor birth defectOther complicationCongenital anomalyNeonatal death
Arm A: Clomiphene Citrate1724120412
Arm B: Letrozole2774521541

[back to top]

Time to Ovulation With Each Protocol

We hypothesized that time to ovulation would be shorter with stair-step protocol vs. traditional. (NCT01008319)
Timeframe: 5 years

Interventiondays (Mean)
Traditional Administration31.1
Stair-Step Administration21.5

[back to top]

Delivery Outcomes

Proportion of participants that delivered a baby based on which protocol they were randomized to. (NCT01008319)
Timeframe: 5 years

InterventionParticipants (Count of Participants)
Traditional Protocol21
Stair-Step Protocol21

[back to top]

Time to Pregnancy

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventiondays (Mean)
Aromatase Inhibitors (AI)67.2
Clomiphene Citrate (CC)67.4
Follicle Stimulating Hormone (FSH)62.3

[back to top]

Rate of Pregnancy Obtained

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventionparticipants (Number)
Aromatase Inhibitors (AI)85
Clomiphene Citrate (CC)106
Follicle Stimulating Hormone (FSH)140

[back to top]

Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH.

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventionnumber of multiples (Number)
Aromatase Inhibitors (AI)9
Clomiphene Citrate (CC)8
Follicle Stimulating Hormone (FSH)34

[back to top]

Live Birth Rate

(NCT01044862)
Timeframe: Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks

Interventionparticipants (Number)
Aromatase Inhibitors (AI)56
Clomiphene Citrate (CC)70
Follicle Stimulating Hormone (FSH)97

[back to top]

Change in HbA1C

The change in HbA1c from Baseline to 3 Months for each treatment arm (NCT01191320)
Timeframe: 3 months

InterventionRatio (Mean)
Placebo0
Androxal 12.5 mg0
Androxal 25 mg0

[back to top]

Change in FSH After 3 Months of Treatment

(NCT01270841)
Timeframe: 3 months

InterventionmIU/mL (Mean)
Placebo-0.2
Testim (Topical Testosterone)-4.4
Androxal 12.5 mg5.1
Androxal 25 mg7.4

[back to top]

Change in Luteinizing Hormone Levels

Changes in values from baseline in LH at month 3 (NCT01270841)
Timeframe: 3 months

InterventionmIU/mL (Mean)
Placebo-0.1
Testim (Topical Testosterone)-2.4
Androxal 12.5 mg4.8
Androxal 25 mg6.9

[back to top]

Change in Total Morning Testosterone

Changes in values from baseline in total morning testosterone levels at month 3 comparing Androxal 12.5 and 25 mg to placebo and Testim (NCT01270841)
Timeframe: 3 months

Interventionng/dL (Mean)
Placebo-16.9
Testim (Topical Testosterone)253.7
Androxal 12.5 mg258.5
Androxal 25 mg197.3

[back to top]

Reproductive Safety

Change from baseline in sperm concentration (NCT01270841)
Timeframe: 3 months

Interventionmillions/mL (Mean)
Placebo-19.1
Testim (Topical Testosterone)-29.5
Androxal 12.5 mg8.2
Androxal 25 mg-2.8

[back to top]

24 Hour Average and Maximum Testosterone Concentration

"The primary efficacy endpoint will be 24-hour average (TTavg) and maximum (TTmax) testosterone concentration compared to baseline after 6 weeks of treatment.~Time points (in hours after dosing) at which testosterone concentration was measured are: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24." (NCT01386606)
Timeframe: Baseline and Week 6

,,,
Interventionng/dL (Mean)
TTavg at BaselineTTavg at Week 6TTmax at BaselineTTmax at Week 6
AndroGel322.4543.9562.3930.1
Androxal 12.5 mg373.6460.8513.7607.5
Androxal 25 mg298.3586.7425.9764.3
Androxal 6.25 mg262.3392.4358.5524.5

[back to top]

Morning Testosterone Correlated With Serial Testosterone.

"9 AM morning testosterone correlated with Week 6 serial testosterone Cavg, Cmin, and Cmax.~If a subject did not have a Week 6 serial testosterone Cavg, Cmin, or Cmax then they were not included for that particular correlation calculation." (NCT01386606)
Timeframe: Week 6

InterventionNumber of Subjects (Number)
Androxal Pooled Dose Levels35

[back to top]

Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.

The Tmax for plasma concentration. (NCT01386606)
Timeframe: Week 6

Interventionh (Mean)
Androxal 6.25 mg2.33
Androxal 12.5 mg2.42
Androxal 25 mg2.41

[back to top]

Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.

The Cmax for plasma concentration. (NCT01386606)
Timeframe: Week 6

Interventionng/mL (Mean)
Androxal 6.25 mg1.8154
Androxal 12.5 mg3.3899
Androxal 25 mg16.2993

[back to top]

Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.

The area under the curve for plasma concentration over time from zero to 24 hours (AUC0-24). (NCT01386606)
Timeframe: Week 6

Interventionng*h/mL (Mean)
Androxal 6.25 mg21.200
Androxal 12.5 mg34.012
Androxal 25 mg150.51

[back to top]

Change in Follicle Stimulating Hormone (FSH)

Changes in morning FSH after continuous dosing (NCT01386606)
Timeframe: Baseline, Week 2, Week 4, Week 6

,,,
InterventionmIU/mL (Mean)
Morning FSH at BaselineMorning FSH at Week 2Morning FSH Change from Baseline at Week 2Morning FSH at Week 4Morning FSH Change from Baseline at Week 4Morning FSH at Week 6Morning FSH Change from Baseline at Week 6
AndroGel6.383.80-2.583.72-2.663.35-3.03
Androxal 12.5 mg5.637.772.147.121.488.192.56
Androxal 25 mg6.3111.415.0912.346.0313.457.14
Androxal 6.25 mg4.616.181.606.451.665.691.42

[back to top]

Change in Leuteinizing Hormone (LH)

Changes in morning LH after continuous dosing (NCT01386606)
Timeframe: Baseline, Week 2, Week 4, Week 6

,,,
InterventionmIU/mL (Mean)
Morning LH at BaselineMorning LH at Week 2Morning LH Change from Baseline at Week 2Morning LH at Week 4Morning LH Change from Baseline at Week 4Morning LH at Week 6Morning LH Change from Baseline at Week 6
AndroGel3.572.00-1.571.88-1.692.2-1.41
Androxal 12.5 mg4.828.603.787.202.388.23.39
Androxal 25 mg4.989.644.6611.786.7914.59.51
Androxal 6.25 mg3.635.491.996.923.436.12.60

[back to top]

Subjects With 50% or Greater Decrease in Sperm Concentration Comparison of Proportion of Subjects With 50% or Greater Decrease in Sperm

"Proportion of subjects with a 50% or greater decrease in sperm concentration from baseline after 12 weeks of treatment in Androxal treated subjects to placebo.~The difference between the proportions (placebo minus Androxal) and corresponding 95% confidence interval was determined and compared to the equivalence limit of -20%. If the lower limit of the 95% confidence interval was greater than -20%, then Androxal would be concluded to be non-inferior to placebo in causing a 50% reduction in sperm concentrations." (NCT01532414)
Timeframe: 3 months

Interventionpercentage of participants (Number)
Androxal Subjects Pooled14.2
Placebo2.6

[back to top]

Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range

"Proportion of pooled Androxal subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment. Cavg will be calculated as the numerical average of 24-hour serial testosterone assessments at 0, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours after dosing.~If the lower limit of the 95% confidence interval for the Androxal treatment group at Week 12 is at least 67%, then the co-primary endpoint based on the Cavg for testosterone has been achieved.~FDA specified primary endpoint did not include comparison to placebo, thus the proportion of placebo subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment was not calculated." (NCT01532414)
Timeframe: 3 months

InterventionPercentage of Subjects (Number)
Androxal Treated Subjects Pooled78.8

[back to top]

Change From Baseline in Total Morning Testosterone at 26 Weeks

Changes in values from baseline of total morning testosterone levels at Week 26 (NCT01534208)
Timeframe: 6 months

Interventionng/dL (Mean)
Androxal 12.5 mg280.9
Androxal 25 mg214.7

[back to top]

Mean Change From Baseline FPG

Mean changes in Fasting Plasma Glucose from baseline to end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

Interventionmg/dL (Mean)
Androxal 12.5 mg-5.4
Androxal 25 mg-5.0

[back to top]

Absolute Values of Morning Testosterone

Absolute values of morning testosterone at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

Interventionng/dL (Mean)
Androxal 12.5 mg511.6
Androxal 25 mg416.7

[back to top]

Change From Baseline in BMI

Mean change from baseline in BMI at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

Interventionkg/m2 (Mean)
Androxal 12.5 mg0.2
Androxal 25 mg0.3

[back to top]

Change From Baseline in FSH

Change from baseline in FSH at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

InterventionU/L (Mean)
Androxal 12.5 mg5.20
Androxal 25 mg5.42

[back to top]

Change From Baseline in LH

Mean change from baseline in LH at end of treatment (26 weeks) (NCT01534208)
Timeframe: 6 months

InterventionmIu/mL (Mean)
Androxal 12.5 mg4.81
Androxal 25 mg4.27

[back to top]

Subjects With Testosterone in Normal Range After Treatment

"Proportion (percent) of subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment. Cavg was calculated as the numerical average of 24-hour serial testosterone assessments at 0, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours after dosing.~If the lower limit of the 95% confidence interval for the Androxal treatment group at Week 12 is at least 67%, then the coprimary endpoint based on the Cavg for testosterone would have been achieved.~FDA specified primary endpoint did not include comparison to placebo, thus the proportion of placebo subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment was not calculated." (NCT01739595)
Timeframe: 3 months

InterventionPercentage of Subjects (Number)
Androxal Subjects Pooled81.3

[back to top]

Change in Sperm Concentration

"Proportion of subjects with a 50% or greater decrease in sperm concentration from baseline after 12 weeks of treatment in Androxal treated subjects to placebo.~The difference between the proportions (placebo minus Androxal) and corresponding 95% confidence interval was determined and compared to the equivalence limit of -20%. If the lower limit of the 95% confidence interval was greater than -20%, then Androxal would be concluded to be non-inferior to placebo in causing a 50% reduction in sperm concentrations." (NCT01739595)
Timeframe: 3 months

Interventionpercentage of subjects (Number)
Androxal Subjects Pooled14.2
Placebo4.3

[back to top]

Androgen Deficiency in the Aging Male (ADAM) Questionnaire

Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 0 and maximum score is 10. 0 is most symptomatic, and 10 is least symptomatic. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionscores on a scale (Mean)
Clomiphene Citrate8.0
Placebo8.0

[back to top]

Estradiol

(NCT01880086)
Timeframe: 3 months post initial visit

Interventionpg/mL (Mean)
Clomiphene Citrate23
Placebo25.2

[back to top]

Hematocrit (%)

Measure hematocrit from baseline. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionpercentage (Mean)
Clomiphene Citrate35.2
Placebo42.3

[back to top]

Men's Sexual Health Questionnaire (MSHQ) Questionnaire

Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 1, maximum score is 20. Minimum score is considered most symptomatic, maximum score is considered least symptomatic. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionscores on a scale (Mean)
Clomiphene Citrate7.0
Placebo8.8

[back to top]

Other Hormonal Profile (Change From Baseline)

Luteinizing hormone (LH) (NCT01880086)
Timeframe: 3 months post initial visit

InterventionIU/mL (Mean)
Clomiphene Citrate3.3
Placebo2.2

[back to top]

Serum Total Testosterone (Change From Baseline)

Morning venipuncture of serum total testosterone. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionng/mL (Mean)
Clomiphene Citrate322.5
Placebo179.8

[back to top]

Sexual Health Inventory for Men (SHIM) Questionnaire

Overall, study subjects will be assessed for possible change in hypogonadal, sexual function, and pain symptoms. Minimum score is 1, maximum score is 25. The minimum value is most symptomatic and maximum value is least symptomatic. (NCT01880086)
Timeframe: 3 months post initial visit

Interventionscores on a scale (Mean)
Clomiphene Citrate12.2
Placebo18.5

[back to top]

Number of Follicles>18mm.

(NCT01909141)
Timeframe: 3 months

Interventionfollicles (Mean)
Arm 1:Letrozole-pioglitazone -Metformin Group1.44
Arm 2: Clomiphene Citrate-pioglitazone-metformin1.5

[back to top]

Pregnancy Rate

(NCT01909141)
Timeframe: 3 months

Interventionparticipants (Number)
Arm 1:Letrozole-pioglitazone -Metformin Group28
Arm 2: Clomiphene Citrate-pioglitazone-metformin24

[back to top]

Safety of Pioglitazone as Regards Serum Creatinine

serum creatinine was measured at the end of the study period (after 3 months) in both groups. (NCT01909141)
Timeframe: 3 months

Interventionmg/dL (Mean)
Arm 1:Letrozole-pioglitazone -Metformin Group0.62
Arm 2: Clomiphene Citrate-pioglitazone-metformin0.57

[back to top]

Ovulation Rate

(NCT01909141)
Timeframe: 3 months

Interventionpercentage of all cycles (Number)
Arm 1:Letrozole-pioglitazone -Metformin Group93
Arm 2: Clomiphene Citrate-pioglitazone-metformin108

[back to top]

Endometrial Thickness

(NCT01909141)
Timeframe: 3 months

Interventionmm (Mean)
Arm 1:Letrozole-pioglitazone -Metformin Group10.56
Arm 2: Clomiphene Citrate-pioglitazone-metformin9.68

[back to top]

Cmax of a Single Dose of 250 mg Androxal

(NCT01959685)
Timeframe: 24 hours

Interventionng/dL (Mean)
Up to 250 mg Androxal24.9

[back to top]

Pharmacokinetics

Cmax of a single dose 125 mg of Androxal (NCT01959685)
Timeframe: 24 hrs

Interventionng/dL (Mean)
Up to 250 mg Androxal11.0

[back to top]

Androxal Cmax Formulation A

To determine and compare the pharmacokinetic parameter Cmax between two formulations of Androxal (NCT01984398)
Timeframe: 24 hours

Interventionng/mL (Mean)
12.5 mg Androxal Formulation A0.999
25 mg Androxal Formulation A1.67

[back to top]

Androxal Cmax Formulation B

To determine and compare the PK parameter Cmax between two formulations of Androxal (NCT01984398)
Timeframe: 24 hours

Interventionng/mL (Mean)
12.5 mg Androxal Formulation B1.08
25 mg Androxal Formulation B1.74

[back to top]

Testosterone Levels

The objective is to compare the change of testosterone value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90). (NCT02274311)
Timeframe: D90

Interventionng/dL (Median)
Clomiphene Citrate282

[back to top]

IGF-1 Levels

The objective is to compare the change of IGF-1 value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90). (NCT02274311)
Timeframe: Day 90

Interventionng/mL (Mean)
Clomiphene Citrate424

[back to top]

PSA Levels

The objective is to compare the change of PSA value assessed in the beginning of the study (day 0), with the value obtained after three months of use of clomiphene citrate (day 90). (NCT02274311)
Timeframe: Day 90

Interventionng/mL (Median)
Clomiphene Citrate2.0

[back to top]

Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter TNF-α . A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg1.77-0.63
Enclomiphene 25 mg1.93-0.35
Placebo1.94-0.70

[back to top]

Change From Baseline in Body Mass Index (BMI) at Week 48

BMI is calculated as weight (kg)/height(cm^2). A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionkg/cm^2 (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg35.45-1.43
Enclomiphene 25 mg37.38-2.29
Placebo38.05-4.38

[back to top]

Change From Baseline in Body Strength (Chest Press Weight) at Week 48

Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpounds (lbs) (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg169.0075.00
Enclomiphene 25 mg180.9376.90
Placebo151.5087.27

[back to top]

Change From Baseline in Body Strength (Leg Press Weight) at Week 48

Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpounds (lbs) (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg466.06406.92
Enclomiphene 25 mg464.20323.80
Placebo580.86351.50

[back to top]

Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter HbA1c. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpercentage of HbA1c (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg5.56-0.34
Enclomiphene 25 mg5.95-0.54
Placebo5.77-0.65

[back to top]

Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48

The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) × fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg4.88-1.14
Enclomiphene 25 mg4.99-0.75
Placebo4.74-1.80

[back to top]

Change From Baseline in Lean Body Mass (LBM) at Week 48

LBM was assessed using dual-energy X-ray absorptiometry (DXA). A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionkg (Mean)
BaselineChange from Baseline to week 48
Enclomiphene 12.5 mg65.233.14
Enclomiphene 25 mg65.602.40
Placebo68.121.05

[back to top]

Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48

The DHT:T ratio was calculated as the value of DHT/value of T using the same units. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionratio (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg0.080.01
Enclomiphene 25 mg0.080.00
Placebo0.070.00

[back to top]

Change From Baseline in Waist Circumference at Week 48

A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventioncm (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg115.34-6.71
Enclomiphene 25 mg120.87-6.52
Placebo123.96-12.62

[back to top]

Change From Baseline in Weight at Week 48

A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionkg (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg114.13-4.36
Enclomiphene 25 mg121.75-6.15
Placebo124.58-14.51

[back to top]

Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48

The T:E2 ratio was calculated as the value of T/value of E2 using the same units. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionratio (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg5.265.11
Enclomiphene 25 mg4.932.89
Placebo5.212.85

[back to top]

Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter CRP. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionmg/dL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg0.250.06
Enclomiphene 25 mg0.35-0.05
Placebo0.35-0.15

[back to top]

Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter DHT. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionnanogram per deciliter (ng/dL) (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg18.7815.13
Enclomiphene 25 mg16.0620.75
Placebo15.734.25

[back to top]

Change From Baseline in Blood Estradiol (E2) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter E2. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg50.04-3.00
Enclomiphene 25 mg48.4313.03
Placebo45.49-11.46

[back to top]

Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter IL-6. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg2.230.56
Enclomiphene 25 mg3.38-0.21
Placebo2.75-0.78

[back to top]

Change From Baseline in Blood Leptin Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter leptin. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionng/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg9.881.14
Enclomiphene 25 mg16.552.63
Placebo15.16-2.27

[back to top]

Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter LH measured in milli-International Units per milliliter (mIU/mL). A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
InterventionmIU/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg3.932.40
Enclomiphene 25 mg3.413.01
Placebo3.510.83

[back to top]

Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48

Quantose-IR is a laboratory-developed test that assesses insulin resistance. Quantose-IR score is based on a linear regression algorithm utilizing the quantitative measures (natural log transformed) of alpha-hydroxybutyrate, oleate, linoleoylglycerophosphocholine and insulin and was designed to estimate the natural log of insulin-induced glucose infusion rate normalized by whole body mass. The algorithm score is converted to the Quantose-IR score within a range of 1-120 by an arithmetic calculation where higher scores denote greater insulin resistance. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
InterventionQuantose-IR score (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg75.74-3.96
Enclomiphene 25 mg76.50-6.59
Placebo78.05-6.50

[back to top]

Change From Baseline in Blood Testosterone (T) Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter T. A positive change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionng/dL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg243.56173.81
Enclomiphene 25 mg218.24237.17
Placebo223.5343.33

[back to top]

Change From Baseline in Blood Glucose Level at Week 48

A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter Glucose. A negative change from Baseline indicates improvement. (NCT02651688)
Timeframe: Baseline (Day 0) to Week 48

,,
Interventionpg/mL (Mean)
BaselineChange from Baseline to Week 48
Enclomiphene 12.5 mg98.39-1.81
Enclomiphene 25 mg101.41-5.25
Placebo97.93-4.33

[back to top]

Uterine Blood Flow

Doppler ultrasound is used to measure the pulsatility index in both uterine arteries. Pulsatility index is a measure of the arterial resistance to blood flow. The higher the value of the pulsatility index, the more resistant the uterine arteries are, and hence the worst the outcome. (NCT02710981)
Timeframe: Day of HCG administration

Interventionindex (Mean)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)2.4
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)1.6

[back to top]

Endometrial Thickness

Transvaginal sonographic measurement of maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus (NCT02710981)
Timeframe: Day of HCG administration

Interventionmillimeter (Mean)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)6.6
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation)9.3

[back to top]

Clinical Pregnancy Rate

Identifying pregnancy through positive urinary HCG test plus sonographic detection of cardiac pulsations (NCT02710981)
Timeframe: At the end of a 28-day menstrual cycle.

InterventionParticipants (Count of Participants)
Clomiphene Citrate Only Group (6th Ovulation Induction Cycle)0
Clomiphene Citrate Plus Sildenafil Vaginal Gel (7th Ovulation3

[back to top]

Endometrial Thickness

Thickness of endometrial lining assessed by ultrasound (NCT02802865)
Timeframe: Cycle day 12-14

Interventionmm (Mean)
Letrozole6.2
Letrozole + Clomiphene8.3

[back to top]

Conception

Conception: a positive serum or urinary test of hCG; No conception: Neither a positive serum or urinary test of hCG (NCT02802865)
Timeframe: 5 weeks after treatment

InterventionParticipants (Count of Participants)
Letrozole3
Letrozole + Clomiphene4

[back to top]

Clinical Pregnancy

Clinical Pregnancy: an intrauterine pregnancy with fetal heart motion determined by ultrasonography; No Clinical Pregnancy: no intrauterine pregnancy with fetal heart motion determined by ultrasonography (NCT02802865)
Timeframe: 6-7 weeks after treatment

InterventionParticipants (Count of Participants)
Letrozole1
Letrozole + Clomiphene3

[back to top]

Live Birth

Live Birth: delivery of a live infant; No Live Birth: no delivery of a live infant (NCT02802865)
Timeframe: 9-10 months after treatment

InterventionParticipants (Count of Participants)
Letrozole1
Letrozole + Clomiphene3

[back to top]

Size of Largest Developing Follicle

Size of largest follicle on ultrasound (NCT02802865)
Timeframe: Cycle day 12-14

Interventionmm (Median)
Letrozole10
Letrozole + Clomiphene16

[back to top]

Pregnancy Loss

Pregnancy Loss: any pregnancy loss including biochemical pregnancy, ectopic pregnancy, and miscarriage; No Pregnancy Loss: no pregnancy loss including biochemical pregnancy, ectopic pregnancy, or miscarriage. (NCT02802865)
Timeframe: 9-10 months after treatment

InterventionParticipants (Count of Participants)
Letrozole2
Letrozole + Clomiphene1

[back to top]

Number of Participants Achieving Ovulation Measured by Mid-luteal Progesterone Level

Ovulation: mid-luteal progesterone > /=3 ng/mL. No ovulation: mid-luteal progesterone <3ng/mL. (NCT02802865)
Timeframe: 7 days following LH surge or at cycle day 21 if no LH surge was detected

InterventionParticipants (Count of Participants)
Letrozole15
Letrozole + Clomiphene27

[back to top]

Number of Developing Follicles

Number of follicles measuring > 10mm on ultrasound (NCT02802865)
Timeframe: Cycle day 12-14

Interventionfollicles (Median)
Letrozole0
Letrozole + Clomiphene1

[back to top]

Multiple Gestation

Multiple Gestation: an intrauterine pregnancy with multiple fetal heart rates determined by ultrasonography; No Multiple Gestation: either no intrauterine pregnancy, or an intrauterine pregnancy with a single fetal heart rate determined by ultrasonography (NCT02802865)
Timeframe: 9-10 months after treatment

InterventionParticipants (Count of Participants)
Letrozole0
Letrozole + Clomiphene0

[back to top]

Post-hoc Analysis on the Percentage Change in Frequency of Moderate and Severe Hot Flashes From Baseline to Week 12; Exposure Response Assessment

Post-hoc exploratory MMRM analysis was conducted to explore the effect of trough plasma concentration at Week12 on the change in frequency of moderate and severe hot flashes from Baseline to Week 12 in subjects with a BMI >25 kg/m2. (NCT03646162)
Timeframe: Day 84

Interventionpercentage of change (Mean)
PK ≥195ng/mL-77.60
PK <195 ng/mL-50.14

[back to top]

Percentage Change in Severity of Moderate to Severe Hot Flashes at 6 Weeks

Change in severity of moderate to severe hot flashes compared to baseline at 6 weeks (NCT03646162)
Timeframe: 6 weeks

Interventionpercentage of change (Mean)
Veru-944 10 mg-0.21
Veru-944 50 mg-0.31
Placebo-0.35

[back to top]

Change of Frequency of Moderate to Severe Hot Flashes at Week 12

Mean change in frequency of moderate to severe hot flashes compared to baseline at weeks 12 (NCT03646162)
Timeframe: Weeks 12

Interventionpercentage of change (Mean)
Veru-944 10 mg-39.94
Veru-944 50 mg-51.95
Placebo-52.70

[back to top]

Change in Severity of Moderate to Severe Hot Flashes at Week 12

Mean change in severity of moderate to severe hot flashes compared to baseline at week 12 (NCT03646162)
Timeframe: Week 12

Interventionpercentage of change (Mean)
Veru-944 10 mg-12.05
Veru-944 50 mg-16.93
Placebo-22.48

[back to top]

Change in Serum SHBG

Change in serum SHBG concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group (NCT03646162)
Timeframe: 84 days

Interventionnmol/L (Mean)
Veru-944 10 mg55.7
Veru-944 50 mg113.5
Placebo54.1

[back to top]

Change in Serum Free Testosterone

Change in serum free testosterone concentration comparing baseline to day 84 (NCT03646162)
Timeframe: 84 days

Interventionng/L (Mean)
Veru-944 10 mg1.16
Veru-944 50 mg1.38
Placebo1.0

[back to top]

Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks

Percentage of change in frequency of moderate to severe hot flashes at 6 weeks (NCT03646162)
Timeframe: 6 weeks

InterventionPercentage of change in frequency (Mean)
Veru-944 10 mg-19.72
Veru-944 50 mg-42.24
Placebo-46.59

[back to top]

Change in Bone Turnover Markers C-telopeptide (CTX)

Change in C-telopeptide concentration at day 84 compared to baseline (NCT03646162)
Timeframe: 84 days

Interventionng/L (Mean)
Veru-944 10 mg419.7
Veru-944 50 mg362.1
Placebo466

[back to top]

Change in Bone Turnover Markers Alkaline Phosphatase

Change in bone specific alkaline phosphatase at day 84 compared to baseline (NCT03646162)
Timeframe: 84 days

Interventionug/L (Mean)
Veru-944 10 mg13.89
Veru-944 50 mg15.72
Placebo13.12

[back to top]

Normalized Testosterone - Week 24

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo214440274

[back to top]

Normalized Testosterone - Week 24

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 24

,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo268269446196
Anastrazole-placebo-clomiphene793519449630
Clomiphene-placebo-anastrazole537531447486

[back to top]

Estradiol - Week 24

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 24

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo16.26.619

[back to top]

Normalized Testosterone - Week 8

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 8

,,,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo484387607545
Anastrazole-placebo-clomiphene757296453676
Clomiphene-anastrazole-placebo566693216592
Clomiphene-placebo-anastrazole1316917527497
Placebo-anastrazole-clomiphene470298139296

[back to top]

SEP #1-3 Cumulative - Week 16

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 13-18
Placebo-clomiphene-anastrazole3

[back to top]

SEP #1-3 Cumulative - Week 16

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo33

[back to top]

SEP #1-3 Cumulative - Week 16

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 16

,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo2343
Clomiphene-placebo-anastrazole1333
Placebo-anastrazole-clomiphene2021
Anastrazole-placebo-clomiphene3333

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 13-18
Placebo-clomiphene-anastrazole30

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

,
Interventionscore on a scale (Number)
Patients 7-12Patients 19-24
Anastrazole-clomiphene-placebo33
Clomiphene-anastrazole-placebo33

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Clomiphene-placebo-anastrazole312

[back to top]

SEP #1-3 Cumulative - Week 24

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 24

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene3333
Placebo-anastrazole-clomiphene2021

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

Interventionscore on a scale (Number)
Patients 1-6Patients 19-24
Placebo-clomiphene-anastrazole31

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Clomiphene-placebo-anastrazole121

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Anastrazole-clomiphene-placebo323
Clomiphene-anastrazole-placebo123

[back to top]

SEP #1-3 Cumulative - Week 8

"Questions 1, 2, and 3 for the Sexual Encounter Profile have been cumulatively added. 1 - yes and 0 - no have been added for questions 1-3 to determine a total value from 0-3.~0-3: cumulative score from SEP questions 1, 2, and 3~Higher values (3) are considered to be a better outcomes relative to lower numbers (0) 3 is better than 2 is better than 1 is better than 0" (NCT03933618)
Timeframe: Week 8

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene3323
Placebo-anastrazole-clomiphene4322

[back to top]

SHBG - Screen

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole26.220.916.9

[back to top]

SHBG - Screen

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

,,,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo13.930.723.528.6
Anastrazole-placebo-clomiphene35.212.617.522
Clomiphene-anastrazole-placebo2023.521.435.5
Clomiphene-placebo-anastrazole31.726.42011.6
Placebo-anastrazole-clomiphene24.126.814.830.6

[back to top]

SHBG - Week 16

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 16

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole33.316.717.2

[back to top]

SHBG - Week 16

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 16

,,,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo22.330.726.839.3
Anastrazole-placebo-clomiphene35.515.317.224.8
Clomiphene-anastrazole-placebo13.826.614.235
Clomiphene-placebo-anastrazole16.43122.813.9
Placebo-anastrazole-clomiphene17.72316.631

[back to top]

SHBG - Week 24

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 24

,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene23.634.117.5
Placebo-clomiphene-anastrazole29.713.817.3

[back to top]

SHBG - Week 24

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 24

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo15.124.433.8

[back to top]

SHBG - Week 24

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 24

,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Clomiphene-placebo-anastrazole25.225.320.113.7
Anastrazole-placebo-clomiphene41.81621.726
Anastrazole-clomiphene-placebo14.633.82923.2

[back to top]

SHBG - Week 8

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 8

Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole23.924.114.3

[back to top]

SHBG - Week 8

Lab Measure of sex hormone binding globulin at the initial encounter and at the ends of week 8, 16, and 24 (NCT03933618)
Timeframe: Week 8

,,,,
Interventionnmol/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1023.426.928.1
Anastrazole-placebo-clomiphene38.212.716.120.1
Clomiphene-anastrazole-placebo18.42621.642.7
Clomiphene-placebo-anastrazole29.827.230.920.9
Placebo-anastrazole-clomiphene21.625.717.630.7

[back to top]

Normalized Testosterone - Week 8

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 8

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole133271270

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Screen

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Baseline

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1111
Anastrazole-placebo-clomiphene1111
Clomiphene-anastrazole-placebo1111
Clomiphene-placebo-anastrazole1111
Placebo-anastrazole-clomiphene1111
Placebo-clomiphene-anastrazole1111

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 16

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole010

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 16

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 16

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1111
Anastrazole-placebo-clomiphene1111
Clomiphene-anastrazole-placebo1111
Clomiphene-placebo-anastrazole1101
Placebo-anastrazole-clomiphene1111

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 24

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole011

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 24

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 24

,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo011
Clomiphene-placebo-anastrazole110

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 24

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 24

,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene0101
Placebo-anastrazole-clomiphene1111
Anastrazole-clomiphene-placebo1101

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 8

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 8

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Anastrazole-clomiphene-placebo111

[back to top]

ADAM (Androgen Deficiency in the Aging Male) Score - Week 8

"Self reported quantification of hypogonadism. 10 yes or no questions.~A positive (yes) questionnaire result is defined as a yes or 1 and a negative (no) questionnaire result is defined as a no or 0 to question 1 or question 7 or any 3 other questions.~Yes (1) represents a better outcome than No (1)~In Data Entry:~Yes - 1 No - 0" (NCT03933618)
Timeframe: Week 8

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene1101
Clomiphene-anastrazole-placebo1011
Clomiphene-placebo-anastrazole1101
Placebo-anastrazole-clomiphene1111
Placebo-clomiphene-anastrazole1001

[back to top]

EHS (Erectile Hardness Score) - Screen

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Baseline

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3333
Anastrazole-placebo-clomiphene3333
Clomiphene-anastrazole-placebo3333
Clomiphene-placebo-anastrazole2223
Placebo-anastrazole-clomiphene3333
Placebo-clomiphene-anastrazole3313

[back to top]

EHS (Erectile Hardness Score) - Week 16

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole421

[back to top]

EHS (Erectile Hardness Score) - Week 16

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 16

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3333
Anastrazole-placebo-clomiphene3341
Clomiphene-anastrazole-placebo2333
Clomiphene-placebo-anastrazole2343
Placebo-anastrazole-clomiphene3301

[back to top]

EHS (Erectile Hardness Score) - Week 24

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole321

[back to top]

EHS (Erectile Hardness Score) - Week 24

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo233

[back to top]

EHS (Erectile Hardness Score) - Week 24

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 24

,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3333
Anastrazole-placebo-clomiphene4341
Clomiphene-placebo-anastrazole2243
Placebo-anastrazole-clomiphene3311

[back to top]

EHS (Erectile Hardness Score) - Week 8

Self reported questionnaire rated 0-4 0=penis does not enlarge, 4=Penis completely hard and fully rigid (NCT03933618)
Timeframe: Week 8

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo1333
Anastrazole-placebo-clomiphene4333
Clomiphene-anastrazole-placebo1333
Clomiphene-placebo-anastrazole1232
Placebo-anastrazole-clomiphene1233
Placebo-clomiphene-anastrazole3411

[back to top]

Estradiol - Screen

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole15.918.615.9

[back to top]

Estradiol - Screen

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 (NCT03933618)
Timeframe: Baseline

,,,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo21.6913.39.5
Anastrazole-placebo-clomiphene8.119.320.115.5
Clomiphene-anastrazole-placebo9.621.316.226.6
Clomiphene-placebo-anastrazole13.511.414.111
Placebo-anastrazole-clomiphene18.410.913.126.8

[back to top]

Estradiol - Week 16

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 16

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole56.928.237

[back to top]

Estradiol - Week 16

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 16

Interventionpg/mL (Number)
Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene21.61528.3

[back to top]

Estradiol - Week 16

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 16

,,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo39.513.120.148.5
Clomiphene-anastrazole-placebo8.912.823.814.8
Clomiphene-placebo-anastrazole17.914.413.115.9
Placebo-anastrazole-clomiphene56.84.94.9

[back to top]

Estradiol - Week 24

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 24

,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene41.185.929.3
Placebo-clomiphene-anastrazole18.111.64.9

[back to top]

Estradiol - Week 24

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 24

,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo22.512.525.522.2
Anastrazole-placebo-clomiphene43.949.136.439.4
Clomiphene-placebo-anastrazole9.559.24.9

[back to top]

Estradiol - Week 8

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 8

Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole20.818.510

[back to top]

Estradiol - Week 8

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 8

Interventionpg/mL (Number)
Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene15.14.910.7

[back to top]

Estradiol - Week 8

Measurement of Estradiol levels at initial encounter and at the end of Weeks 8, 16, and 24 An entered value of 4.9 means the measure was <5 (NCT03933618)
Timeframe: Week 8

,,,
Interventionpg/mL (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo11.279.77.4
Clomiphene-anastrazole-placebo49.870.125.151.7
Clomiphene-placebo-anastrazole94.54533.539.1
Placebo-anastrazole-clomiphene22.59.315.927.4

[back to top]

Free Testosterone - Screen

Measure of Free Testosterone (NCT03933618)
Timeframe: Baseline

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole6.275.829.49

[back to top]

Free Testosterone - Screen

Measure of Free Testosterone (NCT03933618)
Timeframe: Baseline

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo7.286.076.52
Placebo-anastrazole-clomiphene7.865.786.33

[back to top]

Free Testosterone - Screen

Measure of Free Testosterone (NCT03933618)
Timeframe: Baseline

,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo8.46.749.562.19
Anastrazole-placebo-clomiphene6.999.3112.277.27
Clomiphene-placebo-anastrazole8.829.94.867.71

[back to top]

Free Testosterone - Week 16

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 16

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Clomiphene-placebo-anastrazole12.679.636.63
Placebo-clomiphene-anastrazole19.2114.5716.38

[back to top]

Free Testosterone - Week 16

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 16

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo12.2714.711.22

[back to top]

Free Testosterone - Week 16

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 16

,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo14.168.8310.1714.98
Anastrazole-placebo-clomiphene16.375.75.989.46
Placebo-anastrazole-clomiphene17.4713.477.5811.62

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12
Placebo-anastrazole-clomiphene19.3125.27

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene19.3513.7413.54

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole8.6511.6315.49

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo6.2511.096.11

[back to top]

Free Testosterone - Week 24

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 24

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo10.516.1111.825.82
Clomiphene-placebo-anastrazole11.2817.8918.1916.82

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

Interventionng/dl (Number)
Patients 1-6Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene21.815.1820.01

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole2.719.48.91

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo17.7219.3311.37
Placebo-anastrazole-clomiphene12.35.36.04

[back to top]

Free Testosterone - Week 8

Measure of Free Testosterone (NCT03933618)
Timeframe: Week 8

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo19.4615.6321.6117.44
Clomiphene-placebo-anastrazole35.2727.7921.7115.71

[back to top]

FSH - Screen

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Baseline

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.31.84.4

[back to top]

FSH - Screen

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Baseline

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo2.75.71.65.5
Anastrazole-placebo-clomiphene2.43.75.110
Clomiphene-anastrazole-placebo5.53.91.74.5
Clomiphene-placebo-anastrazole4.52.944.4
Placebo-anastrazole-clomiphene3.63.55.75.1

[back to top]

FSH - Week 16

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 16

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole10.72.68.3

[back to top]

FSH - Week 24

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 24

,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo4.14.424.8
Anastrazole-placebo-clomiphene4.815.17.229.7
Clomiphene-placebo-anastrazole5.23.77.25.8

[back to top]

FSH - Week 16

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 16

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene4.33.73.811.4
Clomiphene-anastrazole-placebo4.261.26.2
Clomiphene-placebo-anastrazole5.32.93.34.2
Placebo-anastrazole-clomiphene6.86.511.58.9
Anastrazole-clomiphene-placebo77.21.912.8

[back to top]

FSH - Week 24

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 24

,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene414.510.4
Placebo-clomiphene-anastrazole6.55.25.9

[back to top]

FSH - Week 24

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 24

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo365

[back to top]

FSH - Week 8

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 8

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.42.24.7

[back to top]

FSH - Week 8

Lab Values for follicle stimulating hormone (NCT03933618)
Timeframe: Week 8

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo5.47.7311.3
Anastrazole-placebo-clomiphene4.36.28.320.3
Clomiphene-anastrazole-placebo8.27.81.86.1
Clomiphene-placebo-anastrazole16.23.036.38.1
Placebo-anastrazole-clomiphene4.14.264.4

[back to top]

IIEF (International Index of Erectile Function) Score - Screen

15 item self reported erectile function. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: At baseline

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo34575550
Anastrazole-placebo-clomiphene43574652
Clomiphene-anastrazole-placebo57454155
Clomiphene-placebo-anastrazole41324547
Placebo-anastrazole-clomiphene24553262
Placebo-clomiphene-anastrazole57365818

[back to top]

IIEF (International Index of Erectile Function) Score - Week 16

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 16

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole663359

[back to top]

IIEF (International Index of Erectile Function) Score - Week 16

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 16

,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo45435362
Anastrazole-placebo-clomiphene53566238
Clomiphene-anastrazole-placebo35503751
Clomiphene-placebo-anastrazole45555847
Placebo-anastrazole-clomiphene37381518

[back to top]

IIEF (International Index of Erectile Function) Score - Week 24

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole652745

[back to top]

IIEF (International Index of Erectile Function) Score - Week 24

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 24

Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo424360

[back to top]

IIEF (International Index of Erectile Function) Score - Week 24

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 24

,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo12546052
Clomiphene-placebo-anastrazole52357247
Placebo-anastrazole-clomiphene41451714
Anastrazole-placebo-clomiphene70606559

[back to top]

IIEF (International Index of Erectile Function) Score - Week 8

15 item self reported erectile function over the past 8 weeks. Each item is scored 0-5 with 0=negative response and 5 = positive response with totals of 0-75 (NCT03933618)
Timeframe: Week 8

,,,,,
Interventionscore on a scale (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo25455563
Anastrazole-placebo-clomiphene55515965
Clomiphene-anastrazole-placebo32633270
Clomiphene-placebo-anastrazole20456545
Placebo-anastrazole-clomiphene35372853
Placebo-clomiphene-anastrazole66724325

[back to top]

LH - Screen

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Baseline

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.52.46

[back to top]

LH - Screen

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Baseline

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo3.53.41.16.3
Anastrazole-placebo-clomiphene3.63.83.54.1
Clomiphene-anastrazole-placebo3.82.44.14.7
Clomiphene-placebo-anastrazole6.84.13.35.9
Placebo-anastrazole-clomiphene3.41.73.16.8

[back to top]

LH - Week 16

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 16

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole13.95.213

[back to top]

LH - Week 16

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 16

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo6.86.91.97.8
Anastrazole-placebo-clomiphene4.64.82.14.3
Clomiphene-anastrazole-placebo4.26.32.26.6
Clomiphene-placebo-anastrazole5.44.91.94.9
Placebo-anastrazole-clomiphene8.93.86.47.4

[back to top]

LH - Week 24

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 24

,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene7.710.58.1
Placebo-clomiphene-anastrazole52.97.1

[back to top]

LH - Week 24

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 24

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 19-24
Clomiphene-anastrazole-placebo3.45.94.7

[back to top]

LH - Week 24

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 24

,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo36.12.22.7
Anastrazole-placebo-clomiphene4.112.65.415.1
Clomiphene-placebo-anastrazole6.46.47.65.4

[back to top]

LH - Week 8

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 8

InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole3.63.36.7

[back to top]

LH - Week 8

Luteinizing Hormone levels collected at the initial encounter and at the end of the 8, 16, and 24 week periods. (NCT03933618)
Timeframe: Week 8

,,,,
InterventionIU/L (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-placebo-clomiphene5.146.911.5
Clomiphene-anastrazole-placebo9.910.76.17.5
Clomiphene-placebo-anastrazole17.312.64.76.9
Placebo-anastrazole-clomiphene6.31.937.3
Anastrazole-clomiphene-placebo9.15.22.94.2

[back to top]

Normalized Testosterone - Screen

Normalized at >350ng/dl (NCT03933618)
Timeframe: Baseline

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole315214321

[back to top]

Normalized Testosterone - Screen

Normalized at >350ng/dl (NCT03933618)
Timeframe: Baseline

,,,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo20529334795
Anastrazole-placebo-clomiphene330237328291
Clomiphene-anastrazole-placebo226194268306
Clomiphene-placebo-anastrazole367300206244
Placebo-anastrazole-clomiphene321243148289

[back to top]

Normalized Testosterone - Week 16

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 16

Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-clomiphene-anastrazole696396585

[back to top]

Normalized Testosterone - Week 16

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 16

,,,,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18Patients 19-24
Anastrazole-clomiphene-placebo437337329609
Anastrazole-placebo-clomiphene591200191323
Clomiphene-anastrazole-placebo338451124456
Clomiphene-placebo-anastrazole391403206288
Placebo-anastrazole-clomiphene502520283484

[back to top]

Normalized Testosterone - Week 24

Normalized at >350ng/dl (NCT03933618)
Timeframe: Week 24

,
Interventionng/dl (Number)
Patients 1-6Patients 7-12Patients 13-18
Placebo-anastrazole-clomiphene596972195
Placebo-clomiphene-anastrazole412375487

[back to top]

Changes in Epicatechin Gallate(ECG)

Changes in epicatechin gallate(ECG) from Visit 1 to Visit 4 (end of study). ECG levels measured at 1 hour after taking study medication were used for both visits. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionnM (Median)
EGCG Daily Alone.7.6
EGCG With Clomiphene Citrate64.1
EGCG With Letrozole60.3

[back to top]

Changes in Endometrial Thickness

Changes in endometrial thickness between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionmm (Mean)
EGCG Daily Alone.-1.9
EGCG With Clomiphene Citrate1.4
EGCG With Letrozole0.6

[back to top]

Changes in ALT/SGPT

Changes in alanine aminotransferase /SGPT between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionU/L (Mean)
EGCG Daily Alone.1.1
EGCG With Clomiphene Citrate4.4
EGCG With Letrozole-1.0

[back to top]

Changes in Alkaline Phosphatase

Changes in Alkaline Phosphatase between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionU/L (Mean)
EGCG Daily Alone.-1.5
EGCG With Clomiphene Citrate-5.6
EGCG With Letrozole-6.0

[back to top]

Change in Serum Folate Level Between MTHFR677-Wild Type (WT) Group and MTHFR677-Hetero Group

Change in serum folate levels between MTHFR677-Wild Type (WT) group and MTHFR677-Hetero group (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionng/mL (Mean)
MTHFR677-Wild Type (WT) Group-3.2
MTHFR677-Hetero Group-2.0

[back to top]

Change in Serum Folate Level Between MTHFR1298-Wild Type (WT) Group and MTHFR1298-Hetero Group

Change in serum folate levels between MTHFR1298-Wild Type (WT) group and MTHFR1298-Hetero group (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionng/mL (Mean)
MTHFR1298-Wild Type (WT) Group-1.5
MTHFR1298-Hetero Group-3.8

[back to top]

Change in Serum Folate Level Between DHFR-Wild Type (WT) Group and DHFR-Hetero or Homo Group.

Change in serum folate levels between DHFR-Wild Type (WT) group and DHFR-Hetero or homo group. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionng/mL (Mean)
DHFR-Wild Type (WT) Group-3.9
DHFR-Hetero or Homo Group.-2.1

[back to top]

Changes in Total Bilirubin

Changes in total bilirubin between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionmg/dL (Mean)
EGCG Daily Alone.0.1
EGCG With Clomiphene Citrate0
EGCG With Letrozole0

[back to top]

Changes in Estrogen (E2)

Changes in Estrogen (E2) between the 3 groups. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

Interventionpg/mL (Mean)
EGCG Daily Alone.-50.9
EGCG With Clomiphene Citrate-49.4
EGCG With Letrozole-50.2

[back to top]

Changes in Epigallocatechin (EGC)

Changes in epigallocatechin (EGC) from Visit 1 to Visit 4 (end of study). EGC levels measured at 1 hour after taking study medication were used for both visits. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionnM (Median)
EGCG Daily Alone.-58.9
EGCG With Clomiphene Citrate8.9
EGCG With Letrozole35.4

[back to top]

Changes in Epigallocatechin Gallate (EGCG)

Changes in epigallocatechin gallate (EGCG) from Visit 1 to Visit 4 (end of study). EGCG levels measured at 1 hour after taking study medication were used for both visits. (NCT04177693)
Timeframe: Baseline, and Visit 4 (end of study, up to 40 days)

InterventionnM (Median)
EGCG Daily Alone.5.8
EGCG With Clomiphene Citrate256.3
EGCG With Letrozole86.4

[back to top]